Champions Oncology (CSBR) has been granted a license to use radioactive materials in preclinical studies. This approval allows in-house work utilizing a variety of clinically relevant radionuclides, significantly expanding the organization’s capabilities in the development and assessment of targeted radiotherapeutics. Through this license, Champions Oncology is now uniquely positioned to integrate under one roof radionuclide-based therapeutic testing with the most clinically relevant bank of patient derived xenograft models.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSBR:
- Champions Oncology collaborates with Turbine for data platform
- Champions Oncology Reports Record Revenue and Strategic Growth
- Champions Oncology price target raised to $12 from $8 at Craig-Hallum
- Champions Oncology Achieves Record Revenue and Profit
- CSBR Earnings Report this Week: Is It a Buy, Ahead of Earnings?